Allarity Therapeutics, Inc. - Common stock (NQ:ALLR)

1.068 +0.018 (+1.73%)

Streaming Delayed Price Updated: 9:34 AM EDT, Oct 1, 2026 Add to My Watchlist

Price and Volume

Volume	1,274
Open	1.060
Bid (Size)	1.050 (1,000)
Ask (Size)	1.140 (100)
Prev. Close	1.050
Today's Range	1.060 - 1.068
52wk Range	0.7687 - 1.839
Shares Outstanding	365,173,471
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical Development

September 30, 2026

From Allarity Therapeutics, Inc.

Via GlobeNewswire

Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research

September 28, 2026

From Allarity Therapeutics, Inc.

Via GlobeNewswire

Performance

YTD	-6.3%	-6.3%
1 Month	-24.2%	-24.2%
3 Month	-19.7%	-19.7%
6 Month	-5.5%	-5.5%
1 Year	-32.4%	-32.4%

More News

Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development

September 15, 2026

From Allarity Therapeutics, Inc.

Via GlobeNewswire

Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement

September 11, 2026

From Allarity Therapeutics, Inc.

Via GlobeNewswire

Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign

August 14, 2026

From Allarity Therapeutics, Inc.

Via GlobeNewswire

Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration

July 07, 2026

From Allarity Therapeutics, Inc.

Via GlobeNewswire

Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic

June 30, 2026

From Allarity Therapeutics, Inc.

Via GlobeNewswire

Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026

June 18, 2026

From Allarity Therapeutics, Inc.

Via GlobeNewswire

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

May 15, 2026

From Allarity Therapeutics, Inc.

Via GlobeNewswire

Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm

May 08, 2026

From Allarity Therapeutics, Inc.

Via GlobeNewswire

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign

May 05, 2026

From Allarity Therapeutics, Inc.

Via GlobeNewswire

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office

April 27, 2026

From Allarity Therapeutics, Inc.

Via GlobeNewswire

Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib’s Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer

April 21, 2026

From Allarity Therapeutics, Inc.

Via GlobeNewswire

Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

March 31, 2026

From Allarity Therapeutics, Inc.

Via GlobeNewswire

Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

March 06, 2026

From Allarity Therapeutics, Inc.

Via GlobeNewswire

Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need

February 18, 2026

From Allarity Therapeutics, Inc.

Via GlobeNewswire

Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment

February 03, 2026

From Allarity Therapeutics, Inc.

Via GlobeNewswire

Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders

December 31, 2025

From Allarity Therapeutics, Inc.

Via GlobeNewswire

Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates

November 14, 2025

From Allarity Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Intraday Session ↗

September 22, 2025

Via Benzinga

Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months

September 22, 2025

From Allarity Therapeutics, Inc.

Via GlobeNewswire

Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025

September 17, 2025

From Allarity Therapeutics, Inc.

Via GlobeNewswire

These stocks have an unusual volume in today's session ↗

August 27, 2025

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

August 27, 2025

Via Benzinga

Top stock movements in today's session. ↗

August 26, 2025

Via Chartmill

Frequently Asked Questions

Is Allarity Therapeutics, Inc. - Common stock publicly traded?

Yes, Allarity Therapeutics, Inc. - Common stock is publicly traded.

What exchange does Allarity Therapeutics, Inc. - Common stock trade on?

Allarity Therapeutics, Inc. - Common stock trades on the Nasdaq Stock Market

What is the ticker symbol for Allarity Therapeutics, Inc. - Common stock?

The ticker symbol for Allarity Therapeutics, Inc. - Common stock is ALLR on the Nasdaq Stock Market

What is the current price of Allarity Therapeutics, Inc. - Common stock?

The current price of Allarity Therapeutics, Inc. - Common stock is 1.068

When was Allarity Therapeutics, Inc. - Common stock last traded?

The last trade of Allarity Therapeutics, Inc. - Common stock was at 10/01/26 09:34 AM ET

What is the market capitalization of Allarity Therapeutics, Inc. - Common stock?

The market capitalization of Allarity Therapeutics, Inc. - Common stock is 390.08M

How many shares of Allarity Therapeutics, Inc. - Common stock are outstanding?

Allarity Therapeutics, Inc. - Common stock has 390M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.